The oral drug ZD1839 shows promise for breast cancer prevention, says a study in the Dec. 17 issue of the Journal of the National Cancer Institute.The study found the drug, also known as gefitinib, prevented the development of estrogen receptor(ER)-negative breast cancer in a mouse model.
